Bone Biologics Corp. Files Amendment to S-1 Registration Statement

TL;DR

<b>Bone Biologics Corporation has filed an amendment to its S-1 registration statement, indicating ongoing efforts to comply with SEC regulations for public offerings.</b>

AI Summary

Bone Biologics Corp (BBLGW) filed a Amended IPO Registration (S-1/A) with the SEC on February 23, 2024. Bone Biologics Corporation filed an amendment (S-1/A) to its registration statement with the SEC on February 23, 2024. The company is incorporated in Delaware and its principal executive offices are located in Burlington, MA. The filing is under the Securities Act of 1933, with registration number 333-276771. Bone Biologics Corporation operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry. The company is classified as a non-accelerated filer.

Why It Matters

For investors and stakeholders tracking Bone Biologics Corp, this filing contains several important signals. This S-1/A filing is a procedural step for Bone Biologics Corp. as they prepare for a potential public offering of securities, requiring detailed disclosures to investors. The classification as a non-accelerated filer suggests the company's current market capitalization and public float are below the thresholds for larger filer categories.

Risk Assessment

Risk Level: low — Bone Biologics Corp shows low risk based on this filing. The risk is low as this is a standard regulatory filing (S-1/A) for a company preparing for a public offering, with no immediate financial or operational distress indicated.

Analyst Insight

Monitor future filings for details on the proposed offering, including the number of shares, pricing, and use of proceeds.

Key Numbers

• 333-276771 — Registration Number (SEC Registration Statement Number)
• 2024-02-23 — Filing Date (Date the S-1/A was filed)
• 01803 — ZIP Code (Principal executive office ZIP code)
• 42-1743430 — IRS Number (IRS Employer Identification Number)

Key Players & Entities

• Bone Biologics Corporation (company) — Registrant name
• February 23, 2024 (date) — Filing date
• 333-276771 (registration_number) — Registration statement number
• Delaware (jurisdiction) — State of incorporation
• Burlington, MA (location) — Principal executive offices
• Jeffrey Frelick (person) — Chief Executive Officer
• Harter Secrest & Emery LLP (company) — Legal counsel
• Lowenstein Sandler LLP (company) — Legal counsel

FAQ

Industry Context

Bone Biologics Corporation operates within the medical device sector, specifically focusing on orthopedic applications.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of new securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for detailed information on the proposed securities offering.
2. Track subsequent SEC filings from Bone Biologics Corp. for updates on the offering's progress.
3. Analyze the company's business model and market position in the orthopedic sector.

Year-Over-Year Comparison

This is an amendment to a previous filing, indicating updates or additions to the initial registration statement.

Key Financial Figures

• $0.001 — 2,051 shares of common stock, par value $0.001 per share ("common stock"), together wi
• $3.90 — sumed combined public offering price of $3.90 per share and accompanying warrant (the
• $0 — ur common stock at an exercise price of $0.001, which we refer to as the "pre-fund
• $35,000 — accountable expenses in an amount up to $35,000, legal fees and expenses in the amount
• $100,000 — ees and expenses in the amount of up to $100,000, and for its clearing expenses in the a
• $15,950 — its clearing expenses in the amount of $15,950. In addition, we have agreed to issue t
• $4.88 — rants), at an assumed exercise price of $4.88 per share, which represents 125% of the

Filing Documents

• forms-1a.htm (S-1/A) — 642KB
• ex4-11.htm (EX-4.11) — 127KB
• ex4-12.htm (EX-4.12) — 125KB
• ex4-13.htm (EX-4.13) — 126KB
• ex5-1.htm (EX-5.1) — 38KB
• ex10-17.htm (EX-10.17) — 252KB
• ex23-1.htm (EX-23.1) — 4KB
• forms-1_001.jpg (GRAPHIC) — 7KB
• ex5-1_001.jpg (GRAPHIC) — 5KB
• ex5-1_002.jpg (GRAPHIC) — 2KB
• 0001493152-24-007706.txt (&nbsp;) — 1336KB

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 15 PLAN OF DISTRIBUTION 19 LEGAL MATTERS 21 EXPERTS 21 INFORMATION INCORPORATED BY REFERENCE 21 WHERE YOU CAN FIND MORE INFORMATION 21 iii ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under &ldquo;Where You Can Find More Information.&rdquo; You should carefully read this prospectus as well as additional information described under &ldquo;Information Incorporated by Reference,&rdquo; before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide you with additional information or information different from that contained in this prospectus or from that contained or incorporated by reference in this prospectus filed with the Securities and Exchange Commission (the "SEC"). We do not, and the placement agent and its affiliates do not, take any responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus, or any document incorporated by reference in this prospectus, is accurate only as of its date, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. This prospectus and the information incorporated by reference in this prospectus contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. We obtained the industry and market data in this prospectus from our own research as well as from industry and general publications, surveys and studies conducted by third par

forward-looking statements by terms such as "anticipate," "believe," "continue," "could,"

forward-looking statements by terms such as "anticipate," "believe," "continue," "could," "depend," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements include, but are not limited to, statements concerning the following: our ability to maintain compliance with the Nasdaq listing standards and remain listed on Nasdaq; our projected financial position and estimated cash burn rate; our estimates regarding expenses, future revenues and capital requirements; our ability to continue as a going concern; our need to raise substantial additional capital to fund our operations; the success, cost and timing of our clinical trials; our dependence on third parties in the conduct of our clinical trials; our ability to obtain the necessary regulatory approvals to market and commercialize our product candidates; the ultimate impact of health pandemics or epidemics on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; the potential that results of preclinical and clinical trials indicate our current product candidate or any future product candidates we may seek to develop are unsafe or ineffective; the results of market research conducted by us or others; our ability to obtain and maintain intellectual property protection for our current product candidates; our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or prote

View Full Filing

View this S-1/A filing on SEC EDGAR